Trial Profile

A Pivotal Study of a Gene-Replacement Therapy in Friedreich's Ataxia

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 03 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AVB 202 (Primary)
Indications Friedreich's ataxia
Focus Registrational; Therapeutic Use
Sponsors AavantiBio; Solid Biosciences

Most Recent Events

05 Dec 2022 According to a Solid Biosciences media release, AavantiBio has been acquired and merged with Solid Biosciences.
29 Jan 2020 New trial record
13 Jan 2020 According to a Muscular Dystrophy Association media release, this trial is expected to begin in 2020 (before the end of the year).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com